Pharmafile Logo
Pharmafocus logo
Advanced Search

Celgene

Showing 15 posts of 128 posts found.

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

November 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Celgene, GSK, Novo Nordisk, politics, popular, top 10, vaccines

The biggest news this week came from Israeli biotech Zion Medical after it was announced that HIV drug Gammora was …

News

Former Celgene CEO Bob Hugin loses in US midterm elections

November 7, 2018
Research and Development Bob Hugin, Celgene, Trump, midterms, republican, us politics

Former Celgene CEO Bob Hugin has failed in his bid to win over the people of New Jersey, after voters …

News
celgene_1_02

Celgene’s Otezla impresses at Phase 3 in scalp psoriasis

October 9, 2018
Manufacturing and Production, Research and Development Celgene, pharma, psoriasis

Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine …

News
celgene_1_02

Celgene’s Otezla produces “meaningful benefits” beyond traditional metrics in plaque psoriasis

September 13, 2018
Research and Development Celgene, otezla, pharma, psoriasis

Celgene made its voice heard amongst the chorus of new psoriasis data emerging from the European Academy of Dermatology and …

News
jackie_fouse_hires

Agios appoints Celgene’s Jacqualyn Fouse as new CEO

September 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, COO, Celgene, Jacqualyn Fouse, agios

The Massachusetts-based oncology specialist Agios Pharmaceuticals has appointed former Celgene President and COO Jacqualyn Fouse as their new Chief Executive …

Appointment
celgene_building

Celgene’s Revlimid combo meets Phase 3 goal in relapsed/refractory indolent lymphoma

July 24, 2018
Manufacturing and Production, Research and Development Celgene, Revlimid, lymphoma, pharma

Celgene has lifted the curtain on new Phase 3 data for its combo of Revlimid (lenalidomide) plus rituximab (R2) in …

News
celgene_building

Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3

July 11, 2018
Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma

Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …

News
celgene_1_02

Celgene showcases strong Otezla data in psoriatic arthritis

June 13, 2018
Research and Development Celgene, EULAR, otezla, pharma

Celgene has seized the opportunity at the Annual European Congress of Rheumatology in Amsterdam to reveal positive new data for …

News
david_elkins

Celgene bring in new CFO to steady the ship

June 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …

Appointment
onlinr

Celgene bring in new CFO to steady the ship

June 4, 2018
Medical Communications, Sales and Marketing Celgene, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …

News
hans-bishop_2x

Juno CEO and Co-founder steps down in wake of Celgene acquisition

April 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Juno, appointment, pharma

Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …

Appointment
hans-bishop_2x

Juno CEO and Co-founder steps down in wake of Celgene acquisition

April 25, 2018
Medical Communications, Research and Development Celgene, appointment, juno therapeutics, pharma

Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …

News
celgene_1_02

Celgene’s COO heads to the exit

April 3, 2018
Manufacturing and Production, Medical Communications, Sales and Marketing Celgene, Mark Alles, Scott Smith, biotech, drugs, pharma, pharmaceutical

Celgene has had a rough six months, its share price since the beginning of October has dropped from $146 to …

News
handshake2

bluebird backs own CAR-T prospect, takes option to co-develop with Celgene

March 29, 2018
Sales and Marketing Bluebird Bio, CAR T, CAR-T, Celgene, biotech, drugs, pharma, pharmaceutical

Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Celgene, Lundbeck, Marijuana, Novartis, Roche, Vertex, brexit, cannabis, multiple sclerosis, neuroscience, pharma

As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023